So, you know how sometimes a stock goes up so fast it practically gets windburn? That's what happened to Acurx Pharmaceuticals Inc. (ACXP) on Wednesday, when it shot up 108%. And on Thursday, it's doing what stocks often do after such a wild ride: taking a breather. Shares were down about 13% in premarket trading, which is basically the market's way of saying, "Okay, that was fun, but let's check the gauges."

One of those gauges is the Relative Strength Index (RSI), a common technical indicator. When ACXP's RSI rocketed into the high 80s on Wednesday, it was a classic overbought signal—a flashing light suggesting the rally might have gotten ahead of itself. It's not a prediction of doom, just a sign that the buying frenzy hit a temporary ceiling.

This whole rollercoaster started with some actual news. On Monday, Acurx dropped a clinical update about its lead antibiotic candidate, ibezapolstat. The drug is aimed at treating recurrent C. difficile infection (rCDI), a nasty and persistent gut bug. The company cited Phase 2 data showing a 96% clinical cure rate, which is the kind of number that makes biotech investors sit up straight. They also said enrollment for a new trial would kick off in the fourth quarter.

Now, with the initial excitement cooling, attention is turning to the company's financials. Acurx is scheduled to report its fourth-quarter 2025 earnings on Friday. Analysts are estimating a loss of $1.00 per share. That's still a loss, but it's a notable improvement from the $3.40 per share loss reported a year earlier. For a clinical-stage biopharma, narrowing losses while advancing a promising drug is generally the story you want to see.

The bigger picture plan involves moving ibezapolstat into Phase 3 international studies. That's the expensive, final stage before potentially seeking approval. The company notes this advance is "subject to funding," which is biotech-speak for "we need to raise more money to do this." On the regulatory front, the drug already has some helpful tailwinds: it holds FDA Fast Track and Qualified Infectious Disease Product (QIDP) designations. These can mean a smoother, potentially faster review path if the late-stage data is good.

Let's look at the chart, because the numbers tell a story of extreme moves. Even with Thursday's pullback, ACXP is trading a staggering 162.5% above its 20-day simple moving average (SMA). That's a powerful short-term extension, like a rubber band stretched very tight. It's also 48.3% above its 100-day SMA, suggesting the longer-term trend is still in repair mode. For context, the stock is down about 35% over the past 12 months. Its 52-week range is $1.33 to $21.00, and at recent levels around $5.24, it's hanging out much closer to the low end of that range than the high end.

For traders watching the technicals, key levels to note are resistance around $5.50 and support near $5.00. These are the zones where buying and selling pressure might intensify.

In short, Acurx is experiencing the classic biotech boom-and-settle. A promising data readout fueled a massive, technically overextended rally. Now the stock is cooling off as reality—in the form of earnings and the long, capital-intensive road of drug development—settles back in. The story for investors remains whether the clinical promise of ibezapolstat can eventually translate into sustainable value.